Stocks Hold Modest Gains; Shire Hits New High
at Investor's Business Daily - Wed Jun 25, 12:23PM CDT
Stocks continued to hold modest gains Wednesday afternoon after shaking off early losses caused by disappointing economic data. The Nasdaq and the S&P 500 were up 0.4% and 0.3%, respectively. Meanwhile, the Dow Jones industrial average was up 0.2%....
AbbVie cites tax break as a Shire deal motivator
By TOM MURPHY - AP - Wed Jun 25, 11:50AM CDT
U.S. drugmaker AbbVie sees a compelling tax break behind its roughly $46 billion bid to buy British counterpart Shire, and it expects the deal to expand Shire's global reach as well.
Why AbbVie (ABBV) Stock Is Gaining Today
at The Street - Wed Jun 25, 10:17AM CDT
Shares of AbbVie (ABBV) are up after the pharmaceuticals company presented its strategic rationale for acquiring Shire (SHPG).
Will Shire's Growth Plan Motivate AbbVie to Dig Deeper?
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jun 25, 8:30AM CDT
The market is already looking for AbbVie Inc to sweeten its recently rejected cash-and-shares offer of $46.5 billion for British drug maker Shire . But, by how much? And, assuming AbbVie comes up with yet another offer, will it be enough to...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire Europe - Wed Jun 25, 7:47AM CDT
- Materials for analyst and investor call in respect of possible offer for Shire plc
Vertex's Price Pop by the Numbers: Does It Fly?
Alex Dumortier, CFA, The Motley Fool - Motley Fool - Tue Jun 24, 8:44PM CDT
U.S. stocks finished lower on Tuesday, with the benchmark S&P 500 closing down 0.6%, while the narrower Dow Jones Industrial Average lost 0.7%. The technology-heavy Nasdaq Composite Index fell 0.1%. One Nasdaq component had a banner day,...
Should Dividend Investors Eject AbbVie Stock?
David Williamson, The Motley Fool - Motley Fool - Tue Jun 24, 6:01PM CDT
Dividend aristocrat spin-off AbbVie (NYSE: ABBV) has one of the highest yields in health care, but does that make it one of the sector's top dividend stocks? In this video, Motley Fool Healthcare analyst David Williamson will be grading well...
Takeover Tango: Healthcare's Best Dance Partner Is...
Keith Speights, The Motley Fool - Motley Fool - Tue Jun 24, 4:00PM CDT
Buying a drug company ain't what it used to be. Once upon a time, a larger pharmaceutical firm would make an offer for a smaller company. Said smaller drugmaker would swoon at the immediate gains for its shareholders. The deal would go through --...
AbbVie Raises Outlook amidst Shire Takeover Attempts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:40PM CDT
AbbVie Inc. (ABBV), which is currently looking to buy UK-based Shire (SHPG), raised its 2014 adjusted earnings guidance.
Abbott Labs to Buy Russia-Based Veropharm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:15PM CDT
Abbott Laboratories (ABT) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million to $495 million.
Walgreen Mulls Overseas Tax Move After Earnings Miss
at Investor's Business Daily - Tue Jun 24, 3:04PM CDT
Walgreen (WAG) missed third-quarter earnings forecasts, but shares pared losses Tuesday after the drug store giant confirmed for the first time that it is mulling a move overseas to cut taxes. The No. 1 drug retailer in the U.S. earned 91 cents a...
AstraZeneca Gets a Chance to Prove Its Worth to Pfizer
Brian Orelli, The Motley Fool - Motley Fool - Tue Jun 24, 1:09PM CDT
A company that rejects a buyout proposal with a 45% stock-price premium had better deliver on its case for being worth more than the offer. AstraZeneca gets an early shot to prove its worth tomorrow when a Food and Drug Administration's...
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial